Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B

  • Oldenburg, Johannes M.D., Ph.D.

Dr. Oldenburg reports receiving grants for studies and research from Bayer, Biotest, CSL Behring, Octapharma, Pfizer, Swedish Orphan Biovitrum, and Takeda Pharmaceutical and travel support as well as personal fees for lectures and advisory board meetings from Bayer, Biogen Idec, Biomarin, Biotest, CSL Behring, Chugai, Freeline, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Sparks, Swedish Orphan Biovitrum, and Takeda Pharmaceutical. No other potential conflict of interest relevant to this letter was reported.

New England Journal of Medicine 387(14):p 1336, October 6, 2022. | DOI: 10.1056/NEJMc2210918

Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B

  • Chowdary, Pratima M.D.
  • Shapiro, Susan Ph.D.
  • Makris, Mike M.D.
  • Evans, Gillian M.B., Ch.B.
  • Boyce, Sara M.D.
  • Talks, Kate M.D.
  • Dolan, Gerard M.D.
  • Reiss, Ulrike M.D.
  • Phillips, Mark M.Sc.
  • Riddell, Anne M.Sc.
  • Peralta, Maria R. M.D.
  • Quaye, Michelle B.Sc.
  • Patch, David W. M.D.
  • Tuddenham, Edward M.D.
  • Dane, Allison Ph.D.
  • Watissée, Marie M.Sc.
  • Long, Alison M.D.
  • Nathwani, Amit M.B., Ch.B., Ph.D.
New England Journal of Medicine 387(3):p 237-247, July 21, 2022. | DOI: 10.1056/NEJMoa2119913
Copyright © 2022 Massachusetts Medical Society. All rights reserved.